Keywords: peg-inf, lambda, reduces, hcv, rna, liver, aes
PEG-INF lambda reduces HCV RNA with no liver AEs
Article | 24 April 2009
US drug major Bristol-Myers Squibb and local partner ZymoGenetics reported data showing that the investigational compound PEG-Interferon lambda plus ribavirin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
